The FDA Approves J&J, Bayer's Xarelto
The FDA Approves J&J, Bayer's Xarelto
Introduction
On Monday, Oct.14, Johnson & Johnson's (J&J) subsidiary Janssen Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (rivaroxaban) for the prevention of blood clots in acutely ill patients without a high risk of bleeding during and after hospitalization.
Xarelto is an anticoagulant manufactured by Bayer and jointly marketed by Janssen Pharmaceuticals. Including the latest approval, Xarelto now has eight indications, six of which are specifically for the treatment, prevention, and reduction in the risk of recurrence of blood clotting.
Xarelto has been allegedly linked to causing uncontrollable bleeding, which leads to unexpected serious injuries and even death. Xarelto lawsuits are consolidated under the federal multidistrict litigation (MDL No.2592; In Re: Xarelto (Rivaroxaban) Products Liability Litigation) in the Eastern District of Louisiana.
Comments
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Categories: Opioids
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Categories: Opioids
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…